• Explore /
  • Poster
  • / Pharmacokinetics and safety of an oral ALK inhibitor, ASP3026, observed in a phase I dose escalation trial.

Pharmacokinetics and safety of an oral ALK inhibitor, ASP3026, observed in a phase I dose escalation trial.

Abstract Poster

Authors

Amita Patnaik

Amita Patnaik

START Center for Cancer Care, San Antonio, TX

Amita Patnaik , Patricia LoRusso , Howard A. Ball , Erkut Bahceci , Geoffrey Yuen , Kyriakos P. Papadopoulos , Muaiad Kittaneh , Anthony W. Tolcher

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics

Track

Developmental Therapeutics

Sub Track

Pharmacology

Clinical Trial Registration Number

NCT01401504

Citation

J Clin Oncol 31, 2013 (suppl; abstr 2602)

DOI

10.1200/jco.2013.31.15_suppl.2602

Abstract #

2602

Poster Bd #

9F

Abstract Disclosures

Similar Posters

First Author: Serena Marchetti

First Author: Soohyeon Lee

First Author: Kelly C. Goldsmith

First Author: Sara A. Hurvitz